Detalhe da pesquisa
1.
Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab.
PLoS One
; 19(2): e0293264, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38300937